Department of Sexual Health Medicine, Sydney Local Health District, Sydney, Australia.
The Kirby Institute, UNSW Sydney, Sydney, Australia.
AIDS Care. 2022 May;34(5):626-632. doi: 10.1080/09540121.2021.1884181. Epub 2021 Apr 15.
Heterosexuals living with HIV report feeling additional HIV stigma compared to homosexual men, which may affect clinical outcomes. Yet, beyond routinely collected surveillance data, little is known about the characteristics of individuals who acquire HIV heterosexually and clinical outcomes by mode of sexual acquisition have not been directly compared. Using data from the Australian HIV Observational Database, we compared clinical characteristics of those with heterosexually-acquired (Het-HIV) to homosexually-acquired HIV (Hom-HIV) to investigate any differences and their implications for clinical management. 513 Het-HIV and 1467 Hom-HIV patients were included and contributed 3,127 and 9,457 person-years of follow-up, respectively. Compared with Hom-HIV, Het-HIV were more often born outside Australia (62.5% vs 39.9%, <0.001), less likely to have Hepatitis C (4.8% vs 7.8%, =0.029) and had lower median CD4 counts at diagnosis (292 vs 450 cells/µL, <0.001) and cART initiation (270 vs 340 cells/µL, <0.001). Despite these lower CD4 counts, there were no significant differences between groups for time to the major clinical endpoints of cART initiation, viral suppression, virological failure or all-cause mortality. Het-HIV had a lower risk of loss-to-follow-up than Hom-HIV (aHR 0.78; 95% CI 0.64-0.95). Further studies examining factors associated with, and interventions to inform retention in care are required.
异性恋 HIV 感染者报告称,与男同性恋者相比,他们感到额外的 HIV 耻辱感,这可能会影响临床结果。然而,除了常规收集的监测数据外,对于异性恋获得 HIV 的个体特征以及性获得方式的临床结果,我们知之甚少,也没有直接比较过这两种情况。我们利用澳大利亚 HIV 观察数据库的数据,比较了异性恋获得(Het-HIV)和同性恋获得 HIV(Hom-HIV)的临床特征,以调查任何差异及其对临床管理的影响。共纳入 513 名异性恋获得 HIV 感染者和 1467 名同性恋获得 HIV 感染者,分别随访 3127 人和 9457 人年。与 Hom-HIV 相比,Het-HIV 更常出生在澳大利亚以外(62.5%对 39.9%,<0.001),感染丙型肝炎的可能性更小(4.8%对 7.8%,=0.029),诊断时的中位数 CD4 计数更低(292 对 450 细胞/µL,<0.001)和开始 cART 治疗时(270 对 340 细胞/µL,<0.001)。尽管 CD4 计数较低,但两组之间在 cART 治疗开始、病毒抑制、病毒学失败或全因死亡率的主要临床终点方面没有显著差异。与 Hom-HIV 相比,Het-HIV 失访的风险较低(aHR 0.78;95%CI 0.64-0.95)。需要进一步研究以确定与保留在护理中的相关因素,并制定干预措施。